atai Life Sciences BV
https://www.atai.life/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From atai Life Sciences BV
Finance Watch: VC Mega-Rounds Are Alive And Well
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
Tech Transfer Roundup: Mydecine, Johns Hopkins Pair Up To Study Psychedelics
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
Beckley Psytech To Evaluate Psilocybin In A Rare Debilitating Headache
The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.
Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
-
Digital Health
- Artificial Intelligence
- Other Names / Subsidiaries
-
- atai Life Sciences AG
- EmpathBio